309 related articles for article (PubMed ID: 17874863)
1. Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder.
Olfson M; Marcus SC; Zhang HF; Wan GJ
J Manag Care Pharm; 2007 Sep; 13(7):570-7. PubMed ID: 17874863
[TBL] [Abstract][Full Text] [Related]
2. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
[TBL] [Abstract][Full Text] [Related]
3. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
Marcus SC; Wan GJ; Kemner JE; Olfson M
Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
[TBL] [Abstract][Full Text] [Related]
5. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
[TBL] [Abstract][Full Text] [Related]
6. Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan.
Wang LJ; Yang KC; Lee SY; Yang CJ; Huang TS; Lee TL; Yuan SS; Shyu YC
PLoS One; 2016; 11(8):e0161061. PubMed ID: 27518196
[TBL] [Abstract][Full Text] [Related]
7. Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.
Setyawan J; Hodgkins P; Guérin A; Gauthier G; Cloutier M; Wu E; Erder MH
J Med Econ; 2013 Oct; 16(10):1203-15. PubMed ID: 23937642
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data.
Van Brunt DL; Johnston JA; Ye W; Pohl GM; O'Hara NN
J Manag Care Pharm; 2006 Apr; 12(3):230-8. PubMed ID: 16623607
[TBL] [Abstract][Full Text] [Related]
9. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
[TBL] [Abstract][Full Text] [Related]
10. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
Shyu YC; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Wang LJ
Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
Hennissen L; Bakker MJ; Banaschewski T; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Hollis C; Kovshoff H; McCarthy S; Nagy P; Sonuga-Barke E; Wong IC; Zuddas A; Rosenthal E; Buitelaar JK;
CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
[TBL] [Abstract][Full Text] [Related]
12. Effect of methylphenidate formulation on treatment patterns and use of emergency room services.
Kemner JE; Lage MJ
Am J Health Syst Pharm; 2006 Feb; 63(4):317-22. PubMed ID: 16452517
[TBL] [Abstract][Full Text] [Related]
13. Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands.
van den Ban E; Souverein PC; Swaab H; van Engeland H; Egberts TC; Heerdink ER
Atten Defic Hyperact Disord; 2010 Dec; 2(4):213-20. PubMed ID: 21258431
[TBL] [Abstract][Full Text] [Related]
14. Impact of negative media publicity on attention-deficit/hyperactivity disorder medication in Taiwan.
Wang LJ; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Shyu YC
Pharmacoepidemiol Drug Saf; 2016 Jan; 25(1):45-53. PubMed ID: 26549311
[TBL] [Abstract][Full Text] [Related]
15. A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial.
Childress AC; Uchida CL; Po MD; DeSousa NJ; Incledon B
Clin Ther; 2020 Dec; 42(12):2332-2340. PubMed ID: 33168234
[TBL] [Abstract][Full Text] [Related]
16. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.
Marchetti A; Magar R; Lau H; Murphy EL; Jensen PS; Conners CK; Findling R; Wineburg E; Carotenuto I; Einarson TR; Iskedjian M
Clin Ther; 2001 Nov; 23(11):1904-21. PubMed ID: 11768842
[TBL] [Abstract][Full Text] [Related]
19. Treatment adherence and persistence in adult ADHD: results from a twenty-four week controlled clinical trial with extended release methylphenidate.
Sobanski E; Retz W; Fischer R; Ose C; Alm B; Hennig O; Rösler M
Eur Psychiatry; 2014 Jun; 29(5):324-30. PubMed ID: 24176644
[TBL] [Abstract][Full Text] [Related]
20. The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
Childress A; Belchenko D; Lempa B
Expert Rev Neurother; 2017 Feb; 17(2):113-121. PubMed ID: 27936986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
